King Pharmaceuticals, is a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world's 39th largest pharmaceutical company. On October 12, 2010, King was acquired by Pfizer for $14.25 per share. King produced a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant. King Pharmaceuticals operated manufacturing facilities in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin. They employed approximately 2,700 people including a sales force of over 1,000 individuals. King Pharmaceuticals, Inc. was incorporated in the State of Tennessee in 1993. According to the King Pharmaceutcals, Inc. Form 10-K for the year ended December 31, 2007 filed with the U.S. Securities and Exchange Commission, the wholly owned subsidiaries of King Pharmaceuticals, Inc. are Monarch Pharmaceuticals, Inc.; King Pharmaceuticals Research and Development, Inc.; Meridian Medical Technologies, Inc.; Parkedale Pharmaceuticals, Inc.; King Pharmaceuticals Canada Inc.; and Monarch Pharmaceuticals Ireland Limited. Wikipedia.
King Pharmaceuticals | Date: 2012-07-11
The present invention provides novel crystalline polymorphic forms of 2-cyclohexylmethylidenehydrazino adenosine, also known as binodenoson, methods of making the same, and methods for the manufacture of a pharmaceutical composition by employing such crystal forms, in particular, for the use of binodenoson in a subject, in need thereof, as a pharmacological stress agent to produce coronary vasodilation.
News Article | December 10, 2010
Two companies in the business of distributing video had a good day on Thursday: Netflix beat out the New York Times for a spot on the S&P 500, and Cablevision also joined the index, thanks to King Pharmaceuticals merging with Pfizer. The S&P 500 switchup is good news for the companies, both of which occupy potentially tenuous positions within their respective industries. Cablevision, for example, spent a good portion of October in a messy fight with News Corp over retransmission rights for Fox programming, eventually caving in right before Game 3 of the World Series). Congress may start intervening in such disputes, since cable providers are dependent on companies like Fox for their content. But every retrans battle in recent memory seems to end with customers losing out on content they want, like G4 or the Hallmark Channel, or the content provider getting what they want. Meanwhile, the Hollywood studios that fuel Netflx’s catalog of movies and TV shows are growing increasingly uneasy with Netflix’s rising success. While Netflix is making plenty of deals to add new content, several execs were quoted recently as saying that they saw Netflix as a shark out to steal their content — more than a hint that the company may struggle in the coming months to secure the titles it needs to stay relevant. It’s easy to see why Hollywood might feel threatened — Netflix’s stock is up over 230 percent from last year. But today’s reindexing means a boost in stock prices for both companies and potentially greater stability in the marketplace. It’s no guarantee of success, but these days, there’s really no such thing.
Katz N.,Tufts University |
Katz N.,Analgesic Research |
Sun S.,King Pharmaceuticals |
Johnson F.,King Pharmaceuticals |
And 2 more authors.
Journal of Pain | Year: 2010
ALO-01 (EMBEDA [morphine sulfate and naltrexone hydrochloride] extended-release capsules [King Pharmaceuticals, Inc, Bridgewater, NJ]), indicated for chronic moderate-to-severe pain, is designed to release naltrexone upon tampering (eg, by crushing), reducing morphine-induced subjective effects. This multicenter, randomized, double-blind, crossover study assessed pharmacokinetics, efficacy, and safety of ALO-01 and compared them with extended-release morphine sulfate (ERMS, KADIAN [morphine sulfate extended-release] capsules [Actavis US, Morristown, NJ]) in adults (N = 113) with osteoarthritis pain. Study periods included washout until pain flare (intensity ≥5, 0 to 10; 0 = no pain, 10 = worst pain); dose titration with ERMS (20 to 160mg BID); and randomization to 2 (crossover) 14-day treatment periods with ERMS or ALO-01, separated by 7 days of open-label ERMS. Assessments included pharmacokinetics (morphine, naltrexone), pain scores (0 to 10), Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; Patient Global Assessment of Medication (1 to 5; poor to excellent). Mean score at pain flare was 7.1. Morphine exposure from both formulations at steady state was similar. Plasma naltrexone concentrations were below limit-of-quantification for most patients and, when present, did not impact pain scores. During treatment, mean pain intensity (day 14: ERMS, 2.4; ALO-01, 2.3, P = .31), WOMAC change-from-baseline (mean pain, physical function, composite scores), and adverse event frequency were similar. ALO-01 and ERMS provided similar relief of osteoarthritis pain. Perspective: We present data demonstrating that ALO-01 has steady-state morphine exposure, efficacy, and safety similar to marketed ERMS capsules. Results highlight the potential for morphine in ALO-01 to manage moderate-to-severe osteoarthritis pain, while the sequestered naltrexone does not interfere with efficacy. © 2010 American Pain Society. Source
Setnik B.,King Pharmaceuticals |
Roland C.L.,King Pharmaceuticals |
Cleveland J.M.,King Pharmaceuticals |
Webster L.,Lifetree Clinical Research and Pain Clinic
Pain Medicine | Year: 2011
Objectives. Remoxy® is a water-insoluble, highly viscous oral formulation of oxycodone extended release (ER) currently in development. The primary objective was to determine the abuse potential of Remoxy under fed conditions relative to oxycodone ER and immediate release (IR) under fasted conditions and compared with placebo (treatment group X). A secondary objective was to evaluate abuse potential under reversed fed/fasted conditions (treatment group Y). Design. Phase I randomized double-blind triple-dummy placebo- and active-controlled 6-way crossover study. Setting. A single US site. Patients. Healthy men and women aged 18-50 years who were nondependent, recreational opioid users. Interventions. Remoxy 40mg whole and chewed, oxycodone ER 40mg whole and crushed, oxycodone IR 40mg crushed, and placebo. Outcome Measures. The primary endpoint was the drug liking subscale of the drug effects questionnaire assessed by various pharmacodynamic parameters. Secondary endpoints included additional pharmacodynamic measures, chewing duration, and safety measures. Results. In treatment group X, Remoxy whole (fed) and chewed (fed) had a significantly lower abuse potential compared with oxycodone ER (crushed, fasted) and IR (fasted) based on the majority of pharmacodynamic parameters of interest for the primary endpoint (drug liking subscale) as well as secondary endpoints. Treatment group Y showed generally similar results. Conclusions. The abuse potential of Remoxy when taken whole or chewed was significantly lower than two comparators with known abuse potential, including oxycodone IR and crushed oxycodone ER, under the fed/fasted conditions tested. Remoxy may be associated with a reduced risk potential for abuse. © 2011 Wiley Periodicals, Inc. Source
Gessi S.,The Interdisciplinary Center |
Fogli E.,The Interdisciplinary Center |
Sacchetto V.,The Interdisciplinary Center |
Merighi S.,The Interdisciplinary Center |
And 5 more authors.
Arteriosclerosis, Thrombosis, and Vascular Biology | Year: 2010
OBJECTIVE-: Foam cell (FC) formation by oxidized low-density lipoprotein (oxLDL) accumulation in macrophages is crucial for development of atherosclerosis. Hypoxia has been demonstrated in atherosclerosis and hypoxia-inducible factor-1 (HIF-1) has been shown to promote intraplaque angiogenesis and FC development. As hypoxia induces HIF-1α stabilization and adenosine (ado) accumulation, we investigated whether this nucleoside regulates HIF-1α in FCs. METHODS AND RESULTS-: Ado, under hypoxia, stimulates HIF-1α accumulation by activating all adenosine receptors (ARs). HIF-1α modulation involved extracellular signal-regulated kinase 1/2 (ERK 1/2), p38 mitogen-activated protein kinase (p38 MAPK), and protein kinase B (Akt) phosphorylation in the case of A1, A2A, A2B, and ERK 1/2 phosphorylation in the case of A3 receptors. Ado, through the activation of A3 and A2B receptors, stimulates vascular endothelial growth factor (VEGF) secretion in a HIF-1α-dependent way. Furthermore, ado, through the A2B subtype, induces an increase of Interleukin-8 (IL-8) secretion in a ERK 1/2, p38, and Akt kinase-dependent but not HIF-1α-mediated way. Finally, ado stimulates FC formation, and this effect is strongly reduced by A3 and A2B blockers and by HIF-1α silencing. CONCLUSIONS-: This study provides the first evidence that A3, A2B, or mixed A3/A2B antagonists may be useful to block important steps in the atherosclerotic plaque development ado-induced. © 2010 American Heart Association, Inc. Source